1 August 2019 - The August 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes several new listings:

• Benzathine benzylpenicillin (Bicillin L-A) - new strength
• Bevacizumab (Avastin) - new indication
• Calcium carbonate (Cal-500) - new strength
• Dasatinib monohydrate (Sprycel) - new indication
• Deferiprone (Ferriprox) - new formulation
• Fluticasone furoate (Arnuity) - new formulation of fluticasone
• Ivacaftor (Kalydeco) - new indication
• Lanreotide acetate (Somatuline Autogel) - restriction change
• Testosterone (Testavan) - new formulation
• Tocilizumab (Actemra) - new formulation
• Trastuzumab (Ogivri) - new biosimilar medicine

Read PBS Summary of Changes